Skip to main content
. 2016 Dec;6(4):498–507. doi: 10.1086/688489

Figure 3.

Figure 3

Circulating plasma macrophage migration inhibitory factor (MIF) levels. Median (interquartile range) central vein (CV), right atrium (RA), and pulmonary artery wedge (PAW) macrophage migration inhibitory factor (MIF) levels in patients with portopulmonary hypertension (POPH) versus controls. Both systemic (CV) and pulmonary (PAW) MIF levels were higher in patients with POPH than in controls (CV: 46.68 ng/mL [32.31–76.04] vs. 31.19 ng/mL [26.92–42.17], P = 0.009; PAW: 49.59 [35.90–108.80] vs. 37.78 [21.78–45.53], P = 0.002). There was also a trend toward higher RA MIF levels in patients with POPH (43.35 ng/mL [34.45–51.99] vs. 34.13 ng/mL [27.81–46.19], P = 0.07).